A method of stimulating the synthesis of human and animal patient lung and sinus surfactants for treatment of lung damage needed to increase lung functions, increase oxygen levels, increase the synthesis of nasal nitric oxide and for inhibition of lung fibrosis while reducing, coughing, lung tightness, mouth breathing, and reducing congestion, for treating patients with a pulmonary condition including asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, sleep apnea and lung cancer, includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:sodium pyruvate； a phosphate； a salt of calcium； and, a salt of magnesium. Preferably, the composition is a saline solution.
